Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.91 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.91 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | PGR | P06401 | 3/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | SHBG | P04278 | 2/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL250127 | 0.99 | HIF1A (0.93) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL8801457 | 0.96 | HIF1A (0.98) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL1010584 | 0.96 | HIF1A (0.98) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL1010585 | 0.96 | HIF1A (0.98) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL24900238 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10292969 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL13046615 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10261067 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL5699764 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL6370134 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118251209-A | Hydrocortisone pharmaceutical solution for injection device | 克鲁斯杰克特公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113660952-B | Bispecific antibodies | 小野药品工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC | 2024-04-25 | — | — | US | disclosed |
| CN-110785180-B | Oncolytic viral therapy and immunotherapy | 贝勒医学院 | 2024-04-02 | — | — | CN | disclosed |
| US-11931452-B2 | Topical compositions containing rofecoxib and methods of making and using the same | JF PHARMA TECH LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-11890260-B2 | Compositions for treating acne and dermatological conditions | Ilera Derm LLC (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-111670203-B | bispecific antibodies | 小野药品工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| CN-116615426-A | FGFR inhibitors and methods of making and using the same | 传达治疗有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-1551866-A | Carboxylic acid derivative compounds and drugs containing these compounds as active ingredient | СҰҩƷ��ҵ��ʽ���� | 2004-12-01 | — | — | CN | disclosed |
| CN-1125654-C | Process for preparing gas and gas precursor filled microspheres | IMARX PHARMACEUTICAL CORP (US) | 2003-10-29 | — | — | CN | disclosed |
| CN-1447804-A | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS INC (US) | 2003-10-08 | — | — | CN | disclosed |
| CN-1119173-C | Method for preparing gas-filled liposomes | IMARX PHARMACEUTICAL CORP (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1430505-A | Microspheres for active embolization | BIOSPHERE MEDICAL INC (US) | 2003-07-16 | — | — | CN | disclosed |
| CN-1361688-A | External preparation for skin diseases containing nitroimidazole | SHOEI CO LTD (JP) | 2002-07-31 | — | — | CN | disclosed |
| EP-1197209-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-0953357-A1 | NEPHROTROPIC DRUGS | Drug Delivery System Institute, Ltd. (JP) | 1999-11-03 | — | — | EP | disclosed |
| CN-1215986-A | Method for preparing gas-filled liposomes | IMARX PHARMACEUTICAL CORP (US) | 1999-05-05 | — | — | CN | disclosed |
| CN-1125389-A | Methods of preparing gas and gaseous precursor-filled microspheres | IMARX PHARMACEUTICAL CORP (US) | 1996-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890260-B2 | Compositions for treating acne and dermatological conditions | COQ8A, ATP5ME, AGK | NR3C1 3071/4885HIF1A 1441/4885HSD17B10 271/4885 |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | NR3C1 3071/4885HIF1A 1441/4885HSD17B10 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.